跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CASIRIVIMAB AND IMDEVIMAB - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CASIRIVIMAB AND IMDEVIMAB
Authorized
STANDARD
CASIRIVIMAB AND IMDEVIMAB
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0ee9a2337d5d6afd
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
0ee9a2337d5d6afd
Drug Approval Canada Name
CASIRIVIMAB AND IMDEVIMAB
Product Name
CASIRIVIMAB AND IMDEVIMAB
Status
Authorization By Interim Order Revoked
Status Date
2024-06-21
Original Market Date
2021-07-29
Din
02516705
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
COVID-19 - IO - Authorization , Prescription , Schedule D
Ahfs
08:18.24
Atc Original
J06BD07 CASIRIVIMAB AND IMDEVIMAB
Atc Name
j 06 bd 07
Aig Number
0262970001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
CASIRIVIMAB
1332 MG / 11.1 ML
IMDEVIMAB
1332 MG / 11.1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0ee9a2337d5d6afd
Type
Standard
Back to Health Canada Approvals